Movianto Ceska republika s.r.o
Movianto Ceska republika s.r.o is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A three-period multicenter study, with a randomized-withdrawal, double-blinded, placebo-controlled design to evaluate the clinical efficacy, safety and tolerability of MAS825 in patients with monogenic IL-18 driven autoinflammatory diseases, including NLRC4-GOF, XIAP deficiency, or CDC42 mutations.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A phase IIIb, multi-center, open-label, randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had insufficient response or relapsed after first line steroid treatment (VAYHIT2)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Multicenter, double-blind, randomized, placebo-controlled, dose-response trial with the full-spectrum Cannabis Extract VER-01 in patients with chronic non-specific low back pain
Sponsor Vertanical GmbH
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Movianto Ceska republika s.r.o?
The 2026-10-09 snapshot links Movianto Ceska republika s.r.o to 7 distinct CTIS trials. Recorded services include Medicinal product management, IMP return and destruction, IMP storage, destruction of unused and returned IMP, Local drug supply, among 7 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Movianto Ceska republika s.r.o?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Movianto Ceska republika s.r.o conducted?
The linked trials record locations in 18 countries, including Czechia, Germany, Spain, France, Italy. These are trial locations, not confirmed office locations or countries where Movianto Ceska republika s.r.o delivered services.
What can this page tell me about Movianto Ceska republika s.r.o's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Movianto Ceska republika s.r.o. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Movianto Ceska republika s.r.o.